

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Joel COTTON, et al.

SERIAL NO: 10/500,891

GAU:

FILED: July 7, 2004

EXAMINER:

FOR: PHOSPHINIC PSEUDOPEPTIDE DERIVATIVES FOR THE SELECTIVE INHIBITION OF THE C-TERMINAL ACTIVE SITE OF ANGIOTENSIN I CONVERTING ENZYME (ACE)

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618


Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
255062US0PCTSERIAL NO.
10/500,891

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Joel COTTON, et al.FILING DATE
July 7, 2004

GROUP

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5 476 847	12/19/95	MCKITTRICK, Brian A. et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	0 361 341	04/04/90	EP		NO
	AC	2 781 230	01/21/00	FR (equivalent of US 6482797 & WO 00/01706- with English abstract)		NO
	AD	2 676 059	11/06/92	FR (equivalent of US 5500414)		NO
	AE	0 725 075	08/07/96	EP (equivalent of US 5776903)		NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AF	DEMANGE, L. et al. "Synthesis of phosphinic alanyl-proline surrogates Ala psi (P02R-CH) Pro as potential inhibitors of the human cyclophilin hCyp-18", Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 42, no.36, pages 6295-6297, XP004302932, ISSN: 0040-4039 09/03/2001
AG	DZAU, Victor J. "Tissue Angiotensin and Pathobiology of Vascular Disease: A Unifying Hypothesis", Hypertension. Vol. 37. pages 1047-1052 2001
AH	LINZ, Wolfgang et al. "Contribution of Kinins to the Cardiovascular Actions of Angiotensin-Converting Enzyme Inhibitors", Pharmacological Reviews. Vol. 47, no.1, pages 25-49 1995
AI	SOUBRIER, Florent et al. "Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning", Biochemistry, vol. 85, pages 9386-9390 1998
AJ	WEI, Lei et al. "The Two Homologous Domains of Human Angiotensin I-converting Enzyme are Both Catalytically Active", The Journal of Biological Chemistry, vol.266, no.14, pages 9002-9008 1991
AK	JASPARD, Emmanuel et al. "Differences in the Properties and Enzymatic Specificities of the Two Active Sites of Angiotensin I-converting Enzyme (Kininase II)", The Journal of Biological Chemistry, vol. 268, no. 13, pages 9496-9503 1993
AL	AZIZI, Michel et al. "Acute Angiotensin-converting Enzyme Inhibition Increases the Plasma Level of the Natural Stem Cell Regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline", J. Clin. Invest., vol.97, no. 3, pages 839-844 1996
AM	DIVE, Vincent et al. "RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites", Biochemistry, vol.96, pages 4330-4335 1999
AN	JUNOT, Christophe et al. "RXP 407, a Selective Inhibitor of the N-Domain of Angiotensin I-Converting Enzyme, Blocks in Vivo the Degradation of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro with No Effect on Angiotensin I Hydrolysis", The Journal of Pharmacology and Experimental Therapeutics, vol. 297, no.2, pages 606-611 2001
AO	JIRACEK, Jiri et al. "Development of Highly Potent and Selective Phosphinic Peptide Inhibitors of Zinc Endopeptidase 24-15 Using Combinatorial Chemistry", The Journal of Biological Chemistry, vol.270, no.37, pages 21701-21706 1995
AP	JIRACEK, Jiri et al. "Development of the First Potent and Selective Inhibitor of the Zinc Endopeptidase Neurolysin Using a Systematic Approach Based on Combinatorial Chemistry of Phosphinic Peptides", The Journal of Biological Chemistry, vol.271, no.32, pages 19606-19611 1996
AQ	YIOTAKIS, Athanasios et al. "Protection of the Hydroxyphosphinyl Function of Phosphinic Dipeptides by Adamantyl. Application to the Solid-Phase Synthesis of Phosphinic Peptides", The Journal of Organic Chemistry, vol.61, no.19, pages 6601-6605 1996
AR	VASSILIOU, Stamatia et al. "Phosphinic Pseudo-Tripeptides as Potent Inhibitors of Matrix Metalloproteinases: A Structure-Activity Study", Journal of Medicinal Chemistry, vol.42, no.14, pages 2610-2620 1999
AS	GEORGIADIS, Dimitris et al. "Potent and Selective Inhibition of Zinc Aminopeptidase A (EC 3.4.11.7, APA) by Glutamyl Aminophosphinic Peptides: Importance of Glutamyl Aminophosphinic Residue in the P1 Position", Biochemistry, vol.39, no.5, pages 1152-1155 2000



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 255062US0PCT		SERIAL NO. 10/500,891	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Joel COTTON, et al.			
				FILING DATE July 7, 2004		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AT	GREENE, Theodora W. et al. "The Role of Protective Groups in Organic Synthesis" and "Protection for the Amino Group", Protective Groups in Organic Synthesis, 2 nd ed., pages 1, 309-315 1991					
	AU	BAYLIS, E. et al. "1-Aminoalkylphosphonous Acids. Part 1. Isosteres of the Protein Amino Acids", J. Chem.Soc. Perkin Trans., pages 2845-2853 1984					
	AV	VILLIERAS, J. et al. "The Wittig-Horner Reaction in Heterogenous Media VIII. Cyclisation During the Aldolisation Step from Aqueous Glutaraldehyde", pages 149-157 1986					
	AW	CHEN, Huixiong et al. "Long Lasting Antinociceptive Properties of Enkephalin Degrading Enzyme (NEP and APN) Inhibitor Prodrugs", J. Med. Chem., vol.44, pages 3523-3530 2001					<input type="checkbox"/> Additional References sheet(s) attached
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



U.S. PCT Application Serial No.: 10/500,891
Docket No.: 255062US0PCT

STATEMENT OF RELEVANCY

- 1) References AA-AC, AF have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References _____ have been cited in the corresponding _____ Search Report. A copy of these references is being submitted herewith.
- 3) References AD-AE, AG-AW are discussed in the specification. A copy of these references is being submitted here with.
- 4) References _____ are additional prior art known to Applicant. A copy of these references is being submitted herewith.